Novai is a UK-based biotechnology startup that is commercializing DARC Technology, an innovative retinal biomarker for application in clinical studies related to Age-related Macular Degeneration (AMD) and glaucoma. DARC integrates a unique patented biological component with a cutting-edge AI algorithm and utilizes standard imaging equipment to detect disease activity at the cellular level. This technology enables the assessment of disease activity to measure the impact of current and future treatments and interventions, as well as the identification of non-responders to both existing and new interventions, thereby eliminating the need for costly, ineffective, or unnecessary medical management.